Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18

Report documents

1. Addendum

   Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18

   published on

   21.09.2023

   Document type

   PDF document, 699 kB, EN, not accessible

   Download file : Addendum (PDF document, 699 kB, EN, not accessible)

Additional information

Project details

Project no.

A23-75

Commission

Commission awarded on 25.07.2023 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Mental and emotional wellbeing

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

1. Dossier assessment

   Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A23-18

   Last updated

   21.09.2023

   Status: Commission completed